

## ASX Release

# Anatara Investor Update and Managing Director Appointment

BRISBANE, 8th February 2016: Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the most recent investor presentation and market update, and to announce that Dr Paul Schober has been appointed as Managing Director effective today.

Dr Schober is currently Anatara's Chief Executive Officer.

### For more information please contact:

#### General inquiries

Mel Bridges  
 Chairman, Anatara Lifesciences  
 +61 (0) 413 051 600  
[melbridges@parmacorp.com](mailto:melbridges@parmacorp.com)

Paul Schober  
 CEO, Anatara Lifesciences  
 +61 (0) 412 026 657  
[pschober@anataralifesciences.com](mailto:pschober@anataralifesciences.com)

### About Anatara Lifesciences

Anatara Lifesciences is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach™ is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.



ANATARA  
LIFESCIENCES

# Continuing to Deliver Investor Update

February 2016



# Disclaimer

*The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.*

*Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.*

*Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.*

*Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.*

*Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.*



# Key Financial Details

ASX Code	ANR
Share Price <sup>1</sup>	\$1.50
Market Cap	\$73.93 million
Ordinary Shares <sup>2</sup>	49,288,246
Raised at IPO (October 2014)	\$7 million
Placement and SPP (July 2015)	\$9 million
Current Cash <sup>3</sup>	\$12.8 million
<p>1. As at 4 February 2016</p> <p>2. 13,036,095 shares held by directors, other related parties, and persons who have received shares from these parties are subject to escrow for 24 months from the date of Anantara's listing on the ASX.</p> <p>3. As at 31<sup>st</sup> December 2015</p>	

# ANR Share Price Chart



# Oral therapeutics for gastrointestinal disease

## Detach™


- Natural, non-antibiotic therapeutic that prevents and treats diarrhoea
- Meets the need to reduce antibiotics in animal production
- Unlike antibiotics, Detach™ will not contribute to antimicrobial resistance





# Lead Indication – Pigs

Diarrhoea affects hundreds of millions of piglets born each year



# Market Opportunity is clear

- Urgent need to combat anti-microbial resistance
- Authorities are restricting/banning the use of antibiotics in farm animals, leading to an increased demand for non-antibiotic treatments
- Consumers want their meat to be safe and antibiotic free so retailers are demanding antibiotic free produce
- Pork producers need effective alternatives to antibiotics
- Pork is #1 consumed meat in the world. Global demand for meat is rising





# Detach™

## Poised for swift market entry

- Launch planned in Australia for  
End 2016/Early 2017
- Has a clear path to market
  - *Proven efficacy (therapeutic claims)*
  - *Proven safety - active ingredient is GRAS (generally recognised as safe)*
  - *Manufacturing complete at commercial scale and global supply confirmed*
  - *Regulatory route defined*
- Addresses a major demand – Need for non-antibiotic alternatives
- Introduction of Detach™ is supported by Industry, Government, Retailer & Consumer demand




Current 50 kg scale  
(≈500,000 doses)



1,000 kg capacity  
(≈8,500,000 doses)

# Anatara Achievements



# Exclusive Option to license Detach™ for worldwide commercialisation with Zoetis

- Aggressive program for evaluation of Detach™ in multiple livestock species
- Zoetis will fund cost of validation trials
- Upfront and subsequent cash payments
- Further strengthens Anantara Balance Sheet
- IP remains the sole property of Anantara
- Anantara retains rights to AUS and NZ
- Validation of Detach™ technology



# Zoetis at a glance



- Zoetis (zō-EH-tis) are the **#1 global animal health company**
- **60+ years** of experience in animal health
- **120+ countries** in which Zoetis products are sold
- **\$4.8 billion** annual revenue (2014)
  - 65% revenue from farm animal products
  - 34% revenue from companion animal products
- **10,000 staff** including 3600+ field force
- **8 animal species** – cattle, swine, poultry, sheep, fish, dogs, cats and horses
- **5 product categories** – anti-infectives, vaccines, medicinal feed additives, parasiticides & other pharmaceutical products




# Why Zoetis?

- Discussions with Top 12 Animal Health Companies
- Zoetis
  - Committed to fast track development
  - Fully fund the costs
  - Commitment to food production animals and multiple livestock species
  - Recognise issues with anti-microbial resistance
  - Commitment to address the issue
  - Global regulatory expertise
  - Extensive global reach



# Upcoming Milestones





# Detach™ Key Benefits

- Detach™ is an orally administered non-antibiotic anti-infective
- Safe and effective
- Broad acting and addresses a range of causes of scour – efficacy does not depend on the cause
- Single dose will protect for several days
- Active ingredient is a natural plant based product
- Stable - does not require refrigeration
- Unlike antibiotics, Detach™ will not lead to antimicrobial resistance
- Proven economic benefits for farmers



# Field Trial Summary



## Previous Trials

- 20 positive field trials on commercial farms
- Detach™ safe and effective in several thousand piglets

## Registration Trials

- Successful trial in Spain (ANR 12-001)
- Successful trial in Northern Victoria (ANR 14-001)
- Successful trial in South East Queensland (ANR 15-001)
- Successful results in different age groups, in different geographical locations and under different clinical scenarios (mild and severe conditions)
- Final trial – farm selected and in advanced planning (Back up sites under evaluation)


### DETACH™ FIELD TRIALS



# Detach™ Mode of action

Detach™ does not target the pathogen

Detach™ acts on the underlying cause of diarrhoea



# What Next?


## Detach™ - A Pipeline in a Product

- Other Detach™ presentations:
  - Livestock in-feed
  - Livestock in-water

### **Potential product extensions for the core components of Detach™**

#### **Partnering Opportunities for:**


- Companion animals (cats & dogs – eg. atopic dermatitis)
- Over-the-Counter (OTC) for humans (diarrhoea; anti-inflammatory, eg. inflammatory bowel disease, irritable bowel syndrome)
- Human therapeutic (diarrhoea; anti-inflammatory, eg. IBD, IBS; cancer; lupus)




# Anatara Product Partnering Opportunities

Discovery    Pre-Clinical    Phase I    Phase II    Phase III    Market


## Detach – anti-diarrhoea



## 0019 – anti-inflammatory (eg. IBD, lupus, dermatitis)



## 0026 – immune stimulation (eg. Oncology, anti-parasitic (non-diarrhoea))





ANATARA  
L I F E S C I E N C E S

# Thank you

*“With the world’s meat production needs set to rise 100% by 2050, it is important we act now to develop non-antibiotic treatment options.”*

Dr Mel Bridges, Chairman – Anatara Lifesciences

Mel Bridges, Chairman  
melbridges@parmacorp.com  
+61 413 051 600

Paul Schober, CEO  
pschober@anataralifesciences.com  
+61 412 026 657


Tracey Mynott, CSO  
tmynott@anataralifesciences.com  
+61 405 050 113





# Intellectual Property

- PCT application filed (August 2015)
- Second USA patent filed (August 2015)
- Solid patent strategy in place for further patents to be filed in major territories
- Claims cover the Detach™ formulation, as well as use of the active ingredient and composition of matter for the active components within Bromelain-Rx
- Bromelain-Rx is not the same as common bromelain
- Detach™ formulation has superior efficacy to bromelain or bromelain-Rx alone



IP wall of China



# Board



Dr Mel Bridges  
Chairman



Paul A. Grujic  
Director



Dr Jay Hetzel  
Director



Iain Ross  
Director



Dr Tracie Ramsdale  
Director



Stephen Denaro  
Company Secretary



# Management



Dr Paul Schober  
Chief Executive Officer



Dr Tracey L. Mynott  
Chief Scientific Officer



Damian Wilson  
Business Development



Dr Kevin Woodward  
Regulatory Advisor



Dr David Venables  
Senior Advisor



Hayley van der Meer  
Commercial Manager



Alan Dowling  
Finance

